Ana C M Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana C M Oliveira has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ana Claudia Latronico
Division of Endocrinology, Department of Internal Medicine University of São Paulo Medical School, University of São Paulo São Paulo Brazil
1 shared publication Atecla N L Alves
Laboratório de Cromatografia e Espectrometria de Massa (AE06-LCMS), Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-900, Brasil
1 shared publication- Berenice Bilharinho Mendonca
University of São Paulo
1 shared publication - Daniel F Carvalho
Laboratório de Hormônios e Genética Molecular - LIM/42, Unidade de Endocrinologia do Desenvolvimento, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-900, Brasil
1 shared publication Giselle Y Hayashi
Instituto Jô Clemente , São Paulo 04040-033
1 shared publicationGuiomar Madureira
Laboratório de Hormônios e Genética Molecular - LIM/42, Unidade de Endocrinologia do Desenvolvimento, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-900, Brasil
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2210-2219
Efficacy of Liquid-chromatography and Radioimmunoassay in False-positives’ Drop-off in CAH Newborn Screening
Context The main challenge in congenital adrenal hyperplasia newborn screening (CAH-NBS) is the high rate of false-positive (FP) results, emphasizing the need for specific serum confirmatory tests. Data on the effectiveness of serum 17-hydroxyprogesterone (17OHP) measurements using available methodologies remain limited. Objectives to evaluate the efficacy of confirmatory tests using measurements of serum steroids by radioimmunoassay (RIA) and liquid chromatography tandem mass spectrometry (LC-MS/MS) methodologies. Design and Setting A prospective longitudinal cohort study. Patients data of 708,437 newborns (NBs) were evaluated. Methods neonatal-17OHP (N17OHP) results ≥ 2x 99.5th were recalled for serum dosages by RIA (17OHP), by LC-MS/MS (17OHP, 21-deoxycortisol-21DF, androstenedione-Δ4, cortisol) and positive predictive values (PPV) were determined. Altered hormonal results were submitted to CYP21A2 genotyping. Non-parametric tests and ROC-curves were used. Results Recall rate of N17OHP (first tier) was 0.03% and serum 17OHP levels remained increased in 26% (RIA) and 11% (LC-MS/MS) of NBs, yielding PPV of 30% and 49%, respectively. Fifty-eight NBs were diagnosed with classical forms, and 32 asymptomatic-NBs persisted with increased serum 17OHP levels. ROC-curves between false and true-positive tests disclosed highest diagnostic performance for 17OHP/LC-MS/MS [cutoff 48.3 ng/mL (146.3 nmol/L) = 100%-sensitivity]. The (17OHP+Δ4)/cortisol ratio presented the highest discriminative ability (cutoff 24.9 = 100%-PPV); serum 21DF presented a good performance and was comparable to 17OHP measured by LC–MS/MS (99%-specificity). Conclusion Measurement of 17OHP by LC-MS/MS provides the best performance for serum confirmatory tests and may be complemented by the (17OHP+Δ4)/cortisol ratio analysis. Genotyping is useful mainly to resolve persistently indeterminate biochemical results.
- 11 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2210-2219
Open AccessEfficacy of Liquid-chromatography and Radioimmunoassay in False-positives’ Drop-off in CAH Newborn Screening
Context The main challenge in congenital adrenal hyperplasia newborn screening (CAH-NBS) is the high rate of false-positive (FP) results, emphasizing the need for specific serum confirmatory tests. Data on the effectiveness of serum 17-hydroxyprogesterone (17OHP) measurements using available methodologies remain limited. Objectives to evaluate the efficacy of confirmatory tests using measurements of serum steroids by radioimmunoassay (RIA) and liquid chromatography tandem mass spectrometry (LC-MS/MS) methodologies. Design and Setting A prospective longitudinal cohort study. Patients data of 708,437 newborns (NBs) were evaluated. Methods neonatal-17OHP (N17OHP) results ≥ 2x 99.5th were recalled for serum dosages by RIA (17OHP), by LC-MS/MS (17OHP, 21-deoxycortisol-21DF, androstenedione-Δ4, cortisol) and positive predictive values (PPV) were determined. Altered hormonal results were submitted to CYP21A2 genotyping. Non-parametric tests and ROC-curves were used. Results Recall rate of N17OHP (first tier) was 0.03% and serum 17OHP levels remained increased in 26% (RIA) and 11% (LC-MS/MS) of NBs, yielding PPV of 30% and 49%, respectively. Fifty-eight NBs were diagnosed with classical forms, and 32 asymptomatic-NBs persisted with increased serum 17OHP levels. ROC-curves between false and true-positive tests disclosed highest diagnostic performance for 17OHP/LC-MS/MS [cutoff 48.3 ng/mL (146.3 nmol/L) = 100%-sensitivity]. The (17OHP+Δ4)/cortisol ratio presented the highest discriminative ability (cutoff 24.9 = 100%-PPV); serum 21DF presented a good performance and was comparable to 17OHP measured by LC–MS/MS (99%-specificity). Conclusion Measurement of 17OHP by LC-MS/MS provides the best performance for serum confirmatory tests and may be complemented by the (17OHP+Δ4)/cortisol ratio analysis. Genotyping is useful mainly to resolve persistently indeterminate biochemical results.